参考文献/References:
[1] Simonneau G,Montani D,Celermajer DS,et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension[J]. Eur Respir J,2019,53(1):1801913.
[2] Gall H,Felix JF,Schneck FK,et al. The Giessen pulmonary hypertension registry: survival in pulmonary hypertension subgroups[J]. J Heart Lung Transplant,2017,36(9):957-967.
[3] di Maria MV,Campbell KR,Burkett DA,et al. Parameters of right ventricular function reveal ventricular-vascular mismatch as determined by right ventricular stroke work versus pulmonary vascular resistance in children with pulmonary hypertension[J]. J Am Soc Echocardiogr,2020,33(2):218-225.
[4] Frid MG,Thurman JM,Hansen KC,et al. Inflammation,immunity,and vascular remodeling in pulmonary hypertension; Evidence for complement involvement?[J]. Glob Cardiol Sci Pract,2020,2020(1):e202001.
[5] Scott TE,Kemp-Harper BK,Hobbs AJ. Inflammasomes:a novel therapeutic target in pulmonary hypertension?[J]. Br J Pharmacol,2019,176(12):1880-1896.
[6] Wang Y,Liu X,Shi H,et al. NLRP3 inflammasome,an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases[J]. Clin Transl Med,2020,10(1):91-106.
[7] Dubois H,Wullaert A,Lamkanfi M. General strategies in inflammasome biology[J]. Curr Top Microbiol Immunol,2016,397:1-22.
[8] Man SM,Kanneganti TD. Regulation of inflammasome activation[J]. Immunol Rev,2015,265(1):6-21.
[9] Kelley N,Jeltema D,Duan Y,et al. The NLRP3 inflammasome:an overview of mechanisms of activation and regulation[J]. Int J Mol Sci,2019,20(13):3328.
[10] Wu Q,Liu H,Liao J,et al. Colchicine prevents atrial fibrillation promotion by inhibiting IL-1β-induced IL-6 release and atrial fibrosis in the rat sterile pericarditis model[J]. Biomed Pharmacother,2020,129:110384.
[11] Vecchié A,Bonaventura A,Toldo S,et al. IL-18 and infections:is there a role for targeted therapies?[J]. J Cell Physiol,2021,236(3):1638-1657.
[12] Hu Y,Chi L,Kuebler WM,et al. Perivascular Inflammation in Pulmonary Arterial Hypertension[J]. Cells,2020,9(11):2338.
[13] Stacher E,Graham BB,Hunt JM,et al. Modern age pathology of pulmonary arterial hypertension[J]. Am J Respir Crit Care Med,2012,186(3):261-272.
[14] Groth A,Vrugt B,Brock M,et al. Inflammatory cytokines in pulmonary hypertension[J]. Respir Res,2014,15(1):47.
[15] Joshi AA,Davey R,Rao Y,et al. Association between cytokines and functional,hemodynamic parameters,and clinical outcomes in pulmonary arterial hypertension[J]. Pulm Circ,2018,8(3):2045894018794051.
[16] Simpson CE,Chen JY,Damico RL,et al. Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension[J]. Eur Respir J,2020,55(4):1901761.
[17] Tang C,Luo Y,Li S,et al. Characteristics of inflammation process in monocrotaline-induced pulmonary arterial hypertension in rats[J]. Biomed Pharmacother,2021,133:111081.
[18] Sharma BR,Kanneganti TD. NLRP3 inflammasome in cancer and metabolic diseases[J]. Nat Immunol,2021,22(5):550-559.
[19] 武亚琳,梁斌,杨志明. NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J]. 心血管病学进展,2019,40(6):943-946.
[20] Farkas D,Alhussaini AA,Kraskauskas D,et al. Nuclear factor κB inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats[J]. Am J Respir Cell Mol Biol,2014,51(3):413-425.
[21] Li L,Wei C,Kim IK,et al. Inhibition of nuclear factor-κB in the lungs prevents monocrotaline-induced pulmonary hypertension in mice[J]. Hypertension,2014,63(6):1260-1269.
[22] Sánchez-Gloria JL,Martínez-Olivares CE,Rojas-Morales P,et al. Anti-inflammatory effect of allicin associated with fibrosis in pulmonary arterial hypertension[J]. Int J Mol Sci,2021,22(16):8600.
[23] Yin J,You S,Liu H,et al. Role of P2X7R in the development and progression of pulmonary hypertension[J]. Respir Res,2017,18(1):127.
[24] Villegas LR,Kluck D,Field C,et al. Superoxide dismutase mimetic,MnTE-2-PyP,attenuates chronic hypoxia-induced pulmonary hypertension,pulmonary vascular remodeling,and activation of the NALP3 inflammasome[J]. Antioxid Redox Signal 2013,18(14):1753-1764.
[25] Udjus C,Cero FJ,Halvorsen B,et al. Caspase-1 induces smooth muscle cell growth in hypoxia-induced pulmonary hypertension[J]. Am J Physiol Lung Cell Mol Physiol,2019,316(6):L999-L1012.
[26] Zhang M,Xin W,Yu Y,et al. Programmed death-ligand 1 triggers PASMCs pyroptosis and pulmonary vascular fibrosis in pulmonary hypertension[J]. J Mol Cell Cardiol,2020,138:23-33.
[27] Cero FT,Hillestad V,Sjaastad I,et al. Absence of the inflammasome adaptor ASC reduces hypoxia-induced pulmonary hypertension in mice[J]. Am J Physiol Lung Cell Mol Physiol,2015,309(4):L378-L387.
[28] Gupta M,Wani A,Ahsan AU,et al. Safranal inhibits NLRP3 inflammasome activation by preventing ASC oligomerization[J]. Toxicol Appl Pharmacol,2021,423:115582.
[29] Li Y,Li Y,Li L,et al. PKR deficiency alleviates pulmonary hypertension via inducing inflammasome adaptor ASC inactivation[J]. Pulm Circ,2021,11(4):20458940211046156.
[30] Tang B,Chen GX,Liang M,et al. Ellagic acid prevents monocrotaline-induced pulmonary artery hypertension via inhibiting NLRP3 inflammasome activation in rats[J]. Int J Cardiol,2015,180:134-141.
[31] Sun Y,Lu M,Sun T,et al. Astragaloside Ⅳ attenuates inflammatory response mediated by NLRP-3/calpain-1 is involved in the development of pulmonary hypertension[J]. J Cell Mol Med,2021,25(1):586-590.
[32] Murphy AJ,Kraakman MJ,Kammoun HL,et al. IL-18 production from the NLRP1 inflammasome prevents obesity and metabolic syndrome[J]. Cell Metab,2016,23(1):155-164.
[33] Parpaleix A,Amsellem V,Houssaini A,et al. Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension[J]. Eur Respir J,2016,48(2):470-483.
[34] Trankle CR,Canada JM,Kadariya D,et al. IL-1 Blockade reduces inflammation in pulmonary arterial hypertension and right ventricular failure:a single-arm,open-label,phase ⅠB/Ⅱpilot study[J]. Am J Respir Crit Care Med,2019,199(3):381-384.
[35] Ridker PM,Everett BM,Thuren T,et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med,2017,377(12):1119-1131.
[36] Hashimoto-Kataoka T,Hosen N,Sonobe T,et al. Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension[J]. Proc Natl Acad Sci U S A,2015,112(20):E2677-E2686.
[37] Toshner M,Church C,Harbaum L,et al. Mendelian randomisation and experimental medicine approaches to IL-6 as a drug target in PAH[J]. Eur Respir J,2021,59(1):2002463.
[38]Morisawa D,Hirotani S,Oboshi M,et al. Interleukin-18 disruption suppresses hypoxia-induced pulmonary artery hypertension in mice[J]. Int J Cardiol,2016,202:522-524.
[39] Bruns DR,Buttrick PM,Walker LA. Genetic ablation of interleukin-18 does not attenuate hypobaric hypoxia-induced right ventricular hypertrophy[J]. Am J Physiol Lung Cell Mol Physiol,2016,310(6):L542-L550.
相似文献/References:
[1]胥雪莲,何川.炎症与动脉粥样硬化[J].心血管病学进展,2015,(5):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
XU Xuelian,HE Chuan.Inflammation and Atherosclerosis[J].Advances in Cardiovascular Diseases,2015,(2):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
[2]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(2):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[3]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(2):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[4]宋志平 杨永健.GPR 35在心血管疾病中的研究进展[J].心血管病学进展,2019,(9):1304.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.031]
SONG Zhiping,YANG Yongjian.The Current Progress of GPR 35 in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(2):1304.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.031]
[5]顾佳仪 刘正霞 鲁翔.白介素-1β在冠心病中的研究进展[J].心血管病学进展,2020,(2):125.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.006]
Gu Jiayi,Liu Zhengxia,Lu Xiang.Interleukin-1 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(2):125.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.006]
[6]王辉 蒋永兴 田野.下肢动脉硬化闭塞症：炎症机制与抗炎治疗的研究进展[J].心血管病学进展,2020,(2):179.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.020]
WANG HuiJIANG YongxingTIAN Ye.Peripheral Arterial DiseaseA Research Progress Review of Inflammatory Mechanism and Anti-inflammatory Therapy[J].Advances in Cardiovascular Diseases,2020,(2):179.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.020]
[7]严宁,杨春霞,马娟,等.β-谷甾醇对大鼠心肌缺血再灌注损伤和ERK1/2信号通路的影响[J].心血管病学进展,2020,(3):321.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.026]
YAN Ning,YANG Chunxia,MA Juan,et al.Effects of -sitosterolon Myocardial Ischemia-reperfusion Injury and ERK1/2 Signaling Pathway in Rats[J].Advances in Cardiovascular Diseases,2020,(2):321.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.026]
[8]韩月 朱莉 宋桂仙.白介素-12家族在冠状动脉粥样硬化中的研究进展[J].心血管病学进展,2020,(5):508.[doi:10.16806/j.cnki.issn.1004-3934.20.05.016]
HAN Yue,ZHU Li,SONG Guixian.Interleukin-12 Family in Coronary Atherosclerosis[J].Advances in Cardiovascular Diseases,2020,(2):508.[doi:10.16806/j.cnki.issn.1004-3934.20.05.016]
[9]汪汉,刘汉雄,蔡琳.2019冠状病毒病的心血管表现[J].心血管病学进展,2020,(11):1152.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
WANG Han,LIU Hanxiong,CAI Lin.Cardiovascular Profiles in Corona V irus Disease 2019[J].Advances in Cardiovascular Diseases,2020,(2):1152.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[10]张颖怡 刘金波 刘欢 赵娜 赵红薇 王宏宇.全身动脉粥样硬化斑块与脑梗死的关系：北京血管病变评价研究结果[J].心血管病学进展,2021,(3):277.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.020]
ZHANG YingyiLIU J inboLIU HuanZHAO NaZHAO HongweiWANG Hongyu.The Relationship Between Systematic Atherosclerotic Plaques and Cerebral Infarction:Results from Beijing Vascular Disease Evaluation Study[J].Advances in Cardiovascular Diseases,2021,(2):277.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.020]